Latest & greatest articles for brimonidine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on brimonidine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on brimonidine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for brimonidine

1. Brimonidine

Brimonidine Top results for brimonidine - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for brimonidine The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

2. Difference in vasoconstrictors: oxymetazoline vs. brimonidine. (Abstract)

Difference in vasoconstrictors: oxymetazoline vs. brimonidine. Objective: Topical oxymetazoline and brimonidine are the only medications approved for treating persistent facial erythema of rosacea. This review aims to investigate the efficacy, safety, pharmacodynamics, and pharmacokinetic properties of oxymetazoline and brimonidine. Methods and materials: Phase II and phase III clinical studies evaluating oxymetazoline and brimonidine were assessed to compare their efficacy and safety. Results (...) : In their respective phase III trials, both oxymetazoline and brimonidine met the primary efficacy outcome of having at least a 2-grade decrease from baseline on both the Clinician Erythema Assessment (CEA) and the Subject Self-Assessment (SSA) Scales compared to the vehicle control. Treatment related adverse events of oxymetazoline and brimonidine are most often mild and localized. Conclusions: Topical oxymetazoline and brimonidine are effective for the management of persistent facial erythema associated

2019 Journal of Dermatological Treatment

3. Glaucoma: brinzolamide/brimonidine combination eye drops

Glaucoma: brinzolamide/brimonidine combination eye drops Glaucoma: brinzolamide/brimonidine Glaucoma: brinzolamide/brimonidine combination e combination ey ye drops e drops Evidence summary Published: 17 March 2015 nice.org.uk/guidance/esnm56 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in March 2015. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up (...) -to-date information. Summary In 2 randomised controlled trials in people with glaucoma, brinzolamide/brimonidine combination eye drops were statistically significantly superior to either constituent drug administered alone as monotherapy in reducing intraocular pressure at 3 months. The combination eye drops were non-inferior to brinzolamide plus brimonidine administered concomitantly. Most reported adverse events were mild to moderate and localised, but these were higher in number

2015 National Institute for Health and Clinical Excellence - Advice

4. Treatment of Rosacea With Concomitant Use of Topical Ivermectin 1% Cream and Brimonidine 0.33% Gel: A Randomized, Vehicle-controlled Study. (Abstract)

Treatment of Rosacea With Concomitant Use of Topical Ivermectin 1% Cream and Brimonidine 0.33% Gel: A Randomized, Vehicle-controlled Study. There is currently a lack of data on the simultaneous treatment of different features of rosacea. Individually, ivermectin 1% (IVM) cream and brimonidine 0.33% (BR) gel have demonstrated efficacy on inflammatory lesions and persistent erythema, respectively.To evaluate the efficacy, safety, patient satisfaction, and optimal timing of administration of IVM

2018 Journal of drugs in dermatology : JDD Controlled trial quality: uncertain

5. A Randomized Trial of Fixed-Dose Combination Brinzolamide 1%/Brimonidine 0.2% as Adjunctive Therapy to Travoprost 0.004. Full Text available with Trip Pro

A Randomized Trial of Fixed-Dose Combination Brinzolamide 1%/Brimonidine 0.2% as Adjunctive Therapy to Travoprost 0.004. To evaluate the safety and efficacy of adding fixed-combination brinzolamide 1%/brimonidine 0.2% (BBFC) as adjunctive therapy to travoprost 0.004% (TRAV) in patients with open-angle glaucoma or ocular hypertension.Multicenter, randomized, double-masked, parallel-group phase 4 clinical trial.setting: Multicenter; 32 sites in the United States.Total of 233 patients with open

2016 American Journal of Ophthalmology Controlled trial quality: uncertain

6. In vivo, micro-morphological vascular changes induced by topical brimonidine studied by Dynamic optical coherence tomography. (Abstract)

In vivo, micro-morphological vascular changes induced by topical brimonidine studied by Dynamic optical coherence tomography. Brimonidine is a selective α2 adrenergic receptor agonist with potent vasoconstrictive activity topically used for treatment of facial flushing and erythema caused by rosacea. Direct evidence for the in vivo morphology changes in skin vessels induced by topical application of brimonidine is limited. Dynamic optical coherence tomography is a novel technology that combines (...) conventional OCT with information on flow and thereby provides supplementary information about the microvasculature. Dynamic OCT is non-invasive and creates high-resolution in vivo images of skin to a depth of maximum 2 mm.The objective of this study was to examine and describe micro-morphological skin vessel changes in normal skin exposed to brimonidine gel using Dynamic OCT.A total of 35 healthy subjects from three European clinical dermatology centres were included in the study. A normal skin area

2016 Journal of the European Academy of Dermatology and Venereology

7. Simbrinza - brinzolamide / brimonidine tartrate

Simbrinza - brinzolamide / brimonidine tartrate 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom An agency of the European Union Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7455 E-mail info@ema.europa.eu Website www.ema.europa.eu 22 May 2014 EMA/366328/2014 Committee for Medicinal Products for Human Use (CHMP) Assessment report Simbrinza International non-proprietary name: Brinzolamide / Brimonidine tartrate Procedure No. EMEA/H/C/003698/0000 Note Assessment report (...) 73 2.6.1. Discussion on clinical safety 74 2.6.2. Conclusions on the clinical safety 76 2.7. Pharmacovigilance 77 2.8. Risk Management Plan 77 2.9. User consultation 78 3. Benefit-Risk Balance 79 4. Recommendations 83 Assessment report EMA/366328/2014 Page 4/83 List of abbreviations Abbreviation/Term Definition a2 Alpha 2 ADR Adverse drug reaction AE Adverse event AUC Area under the curve BAK Benzalkonium chloride BID Two times daily (Bis in Die) Brinz/Brim Brinzolamide /Brimonidine 10mg/mL + 2

2014 European Medicines Agency - EPARs

8. Mirvaso - brimonidine

Mirvaso - brimonidine 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom An agency of the European Union Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8416 E-mail info@ema.europa.eu Website www.ema.europa.eu © European Medicines Agency, 2014. Reproduction is authorised provided the source is acknowledged. 19 December 2013 EMA/CHMP/115246/2014 Committee for Medicinal Products for Human Use (CHMP) Assessment report Mirvaso International non-proprietary name: brimonidine (...) Procedure No. EMEA/H/C/002642/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Assessment Report EMA/CHMP/115246/2014 Page 2/107 Product information Name of the medicinal product: Mirvaso Applicant: Galderma International Tour Europlaza, 20 avenue André Prothin – La Défense 4 La Défense Cedex 92927 France Active substance: Brimonidine tartrate International Nonproprietary Name: Brimonidine Pharmaco-therapeutic group (ATC Code): Other

2014 European Medicines Agency - EPARs

9. Brimonidine gel for the treatment of recalcitrant facial erythema in diseases other than rosacea: a novel tool for clinicians. (Abstract)

Brimonidine gel for the treatment of recalcitrant facial erythema in diseases other than rosacea: a novel tool for clinicians. 26990727 2017 05 01 2017 05 01 1468-3083 31 1 2017 Jan Journal of the European Academy of Dermatology and Venereology : JEADV J Eur Acad Dermatol Venereol Brimonidine gel for the treatment of recalcitrant facial erythema in diseases other than rosacea: a novel tool for clinicians. e32-e33 10.1111/jdv.13618 Del Barrio-Díaz P P Department of Dermatology, Facultad de (...) Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile. Moll-Manzur C C Department of Dermatology, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile. Vera-Kellet C C Department of Dermatology, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile. eng Case Reports Letter 2016 03 16 England J Eur Acad Dermatol Venereol 9216037 0926-9959 0 Gels 4S9CL2DY2H Brimonidine Tartrate IM Adult Brimonidine Tartrate administration & dosage

2016 Journal of the European Academy of Dermatology and Venereology

10. Brimonidine Tartrate Ophthalmic Solution

Brimonidine Tartrate Ophthalmic Solution Drug Approval Package: Brimonidine Tartrate NDA #021764 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Brimonidine Tartrate Ophthalmic Solution Company: Alcon, Inc. Application No.: 021764 Approval Date: 05/22/2006 (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created: February 22, 2008 Note: Documents in PDF format require the . - - Links on this page: Note: If you need help accessing

2006 FDA - Drug Approval Package

11. Simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension)

Simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension) Drug Approval Package: SIMBRINZA (brinzolamide/brimonidine tartrate) NDA #204251 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - SIMBRINZA (brinzolamide/brimonidine tartrate ophthalmic suspension), 1%/0.2% Company: Alcon Research, Ltd Application No.: 204251 Approval Date: 04/19/2013 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634

2013 FDA - Drug Approval Package

12. Mirvaso (brimonidine) Topical Gel

Mirvaso (brimonidine) Topical Gel Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Mirvaso (brimonidine) Topical Gel Company: Galderma Research and Development Inc. Application No.: 204708 Approval Date: 8/23/2013 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

2013 FDA - Drug Approval Package

13. Effects of Brimonidine and Timolol on the Progression of Visual Field Defects in Open-angle Glaucoma: A Single-center Randomized Trial. (Abstract)

Effects of Brimonidine and Timolol on the Progression of Visual Field Defects in Open-angle Glaucoma: A Single-center Randomized Trial. PRéCIS:: Instillation of brimonidine or timolol slowed visual field deterioration in patients with open-angle glaucoma; both brimonidine and timolol might improve the mean deviation (MD) slopes.The purpose of this study was to investigate and compare the effects of 0.1% brimonidine and 0.5% timolol on the progressing visual field defects in open-angle (...) glaucoma.We evaluated 1 eye each of 68 glaucoma patients who were treated with at least 1 prostaglandin analog. Their baseline MD slopes were < -0.5 dB/y based on at least 5 Humphrey field analyzer measurements within 3 years. Eligible eyes were randomly assigned to brimonidine or timolol treatment groups and treatments were administered without the wash-out period. Clinical examinations were performed every 4 months for 2 years. We designated the MD slope as the primary endpoint.Ultimately, 56 eyes

2019 Journal of Glaucoma Controlled trial quality: uncertain

14. Topical Treatment With Brimonidine and Somatostatin Causes Retinal Vascular Dilation in Patients With Early Diabetic Retinopathy From the EUROCONDOR. Full Text available with Trip Pro

Topical Treatment With Brimonidine and Somatostatin Causes Retinal Vascular Dilation in Patients With Early Diabetic Retinopathy From the EUROCONDOR. Structural retinal microvascular changes have been identified as risk markers of diabetic retinopathy (DR). In order to estimate the retinal response of neuroprotective eye drops, we aimed to evaluate the effect of topical retinal neuroprotection on retinal microvascular changes in early DR.Patients with type 2 diabetes with no or early DR were (...) randomized 1:1:1 to topical treatment with placebo, brimonidine, or somatostatin in a 96-week prospective, phase II to III, European multicenter trial. Retinal vascular calibers were measured semiautomatically in digital fundus images by certified graders at baseline and follow-up and summarized as central retinal arteriolar and venular equivalent (CRAE and CRVE).Of 449 patients originally included, 297 completed the study with gradable retinal images. Median age and duration of diabetes was 64.5 and 9.9

2019 Investigative Ophthalmology & Visual Science Controlled trial quality: uncertain

15. Facial erythema of rosacea: brimonidine tartrate gel

Facial erythema of rosacea: brimonidine tartrate gel Facial erythema of rosacea: brimonidine tartr Facial erythema of rosacea: brimonidine tartrate ate gel gel Evidence summary Published: 8 July 2014 nice.org.uk/guidance/esnm43 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in July 2014. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up- to-date (...) information. Summary In 2 short-term randomised controlled trials (RCTs: n=553) brimonidine tartrate gel was statistically significantly more effective than vehicle gel in reducing erythema in people with a clinical diagnosis of rosacea and moderate to severe erythema. However, 'success rates' (defined as a 2-grade reduction in the severity of erythema as assessed by both patients and clinicians) were just 25% to 30% with brimonidine gel compared with about 10% for vehicle gel at day 29. © NICE 2018. All

2014 National Institute for Health and Clinical Excellence - Advice

16. Brimonidine (Mirvaso®)

Brimonidine (Mirvaso®) Brimonidine (Mirvaso®) Brimonidine (Mirvaso®) All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Brimonidine (Mirvaso®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG (...) Secretariat Assessment Report Advice No. 2168. 2015 Authors' conclusions Brimonidine (Mirvaso®) is recommended for restricted use within NHS Wales for the symptomatic treatment of facial erythema of rosacea in adult patients. Brimonidine (Mirvaso®) should be restricted for use in patients with moderate to severe persistent facial erythema associated with rosacea. Brimonidine (Mirvaso®) is not recommended for use within NHS Wales outside of this subpopulation. Final publication URL Indexing Status Subject

2015 Health Technology Assessment (HTA) Database.

17. Efficacy of three different formulations of brimonidine for control of intraocular pressure in primary open-angle glaucoma: A 6-week randomized trial. (Abstract)

Efficacy of three different formulations of brimonidine for control of intraocular pressure in primary open-angle glaucoma: A 6-week randomized trial. To compare the intraocular pressure (IOP)-lowering efficacy and safety of brimonidine (0.2%), brimonidine purite (0.15%), and brimonidine purite (0.1%) in patients of primary open-angle glaucoma (POAG).Sixty patients of POAG with IOP >21 mmHg were enrolled into this study for 6-week duration. The patients were randomly divided into three groups (...) with 20 patients in each group. Group A instilled brimonidine 0.2%, Group B instilled brimonidine purite 0.15%, and Group C instilled brimonidine purite 0.1% twice daily. IOP was recorded by applanation tonometry at baseline and subsequently at 2, 4, and 6 weeks at 9:00-10:00 am during each visit around 30 min after instillation of eye drops.Mean IOP reduction in Group A was from 25.55 ± 2.01 to 19.85 ± 2.05 mmHg at the end of study, thus resulting in fall of 5.70 mmHg (22.30%), in Group B

2019 Oman journal of ophthalmology Controlled trial quality: uncertain

18. Topical brimonidine reduces IPL-induced erythema without affecting efficacy: A randomized controlled trial in patients with facial telangiectasias. (Abstract)

Topical brimonidine reduces IPL-induced erythema without affecting efficacy: A randomized controlled trial in patients with facial telangiectasias. Laser and intense pulsed light (IPL) are standard symptomatic treatments for superficial telangiectasias, but postoperative erythema, oedema, and pain may prolong downtime.To investigate whether topical brimonidine reduces IPL-induced inflammation in patients with moderate to severe facial telangiectasias.A randomized, two-centre, single-blinded (...) , split-face trial on adjuvant brimonidine and air-cooling versus air-cooling alone (control) in 19 patients treated in Denmark (n = 10 patients) and Belgium (n = 9). Brimonidine was applied to the allocated side after each of three facial IPL-treatments, given at 3-week intervals. Patients were assessed up to 1 month after the final treatment. Outcome measures included blinded clinical on-site evaluation of erythema and oedema (5-point-scales), objective erythema-scores (red-filter analysis), patient

2018 Lasers in surgery and medicine Controlled trial quality: uncertain

19. Erratum to: Multicenter, Randomized, Investigator-Masked Study Comparing Brimonidine Tartrate 0.1% and Timolol Maleate 0.5% as Adjunctive Therapies to Prostaglandin Analogues in Normal-Tension Glaucoma. Full Text available with Trip Pro

Erratum to: Multicenter, Randomized, Investigator-Masked Study Comparing Brimonidine Tartrate 0.1% and Timolol Maleate 0.5% as Adjunctive Therapies to Prostaglandin Analogues in Normal-Tension Glaucoma. 28856599 2018 11 02 1865-8652 34 9 2017 09 Advances in therapy Adv Ther Erratum to: Multicenter, Randomized, Investigator-Masked Study Comparing Brimonidine Tartrate 0.1% and Timolol Maleate 0.5% as Adjunctive Therapies to Prostaglandin Analogues in Normal-Tension Glaucoma. 2179 10.1007/s12325

2017 Advances in therapy Controlled trial quality: uncertain

20. Effects of acute topical administration of clonidine 0.125%, apraclonidine 1.0% and brimonidine 0.2% on visual field parameters and ocular perfusion pressure in patients with primary open-angle glaucoma. (Abstract)

Effects of acute topical administration of clonidine 0.125%, apraclonidine 1.0% and brimonidine 0.2% on visual field parameters and ocular perfusion pressure in patients with primary open-angle glaucoma. 12390124 2003 01 30 2015 11 19 1395-3931 236 2002 Acta ophthalmologica Scandinavica. Supplement Acta Ophthalmol Scand Suppl Effects of acute topical administration of clonidine 0.125%, apraclonidine 1.0% and brimonidine 0.2% on visual field parameters and ocular perfusion pressure in patients (...) with primary open-angle glaucoma. 29-30 Sebastiani A A Department of Ophthalmology, University of Ferrara, Italy. Parmeggiani F F Costagliola C C Ciancaglini M M D'Oronzo E E Mastropasqua L L eng Clinical Trial Comparative Study Journal Article Randomized Controlled Trial Denmark Acta Ophthalmol Scand Suppl 9516974 1395-3931 0 Adrenergic alpha-Agonists 0 Quinoxalines 4S9CL2DY2H Brimonidine Tartrate 843CEN85DI apraclonidine MN3L5RMN02 Clonidine IM Administration, Topical Adrenergic alpha-Agonists

2003 Acta ophthalmologica Scandinavica. Supplement Controlled trial quality: uncertain